Evolent Health price target lowered to $41 from $44 at Canaccord

Canaccord lowered the firm’s price target on Evolent Health to $41 from $44 and keeps a Buy rating on the shares. The firm said the company handily beat consensus revenue as well as above the high end of quarterly guide, with adjusted EBITDA coming roughly in line with Street estimates, slightly below the midpoint of prior quarterly guide while noting the company raised revenue guidance for the year.